Gilead Sciences Inc. (GILD) Insider John C. Martin Sells 100,000 Shares
Gilead Sciences Inc. (NASDAQ:GILD) insider John C. Martin sold 100,000 shares of the business’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $77.63, for a total value of $7,763,000.00. Following the sale, the insider now owns 3,231,096 shares in the company, valued at approximately $250,829,982.48. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 0.308% on Friday, hitting $75.975. The company had a trading volume of 1,010,356 shares. The firm has a 50-day moving average price of $79.10 and a 200 day moving average price of $85.17. The company has a market capitalization of $100.26 billion, a P/E ratio of 6.668 and a beta of 1.10. Gilead Sciences Inc. has a 12-month low of $75.75 and a 12-month high of $111.11.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.02 by $0.06. The firm earned $7.78 billion during the quarter, compared to analysts’ expectations of $7.80 billion. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The company’s quarterly revenue was down 5.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.15 EPS. Equities analysts expect that Gilead Sciences Inc. will post $11.76 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were issued a $0.47 dividend. The ex-dividend date of this dividend was Wednesday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.47%. Gilead Sciences’s dividend payout ratio is presently 16.56%.
Institutional investors have recently bought and sold shares of the company. Carroll Financial Associates Inc. boosted its position in Gilead Sciences by 7.2% in the first quarter. Carroll Financial Associates Inc. now owns 4,815 shares of the biopharmaceutical company’s stock worth $442,000 after buying an additional 325 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in Gilead Sciences by 7.2% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 11,323 shares of the biopharmaceutical company’s stock worth $1,057,000 after buying an additional 765 shares during the period. Boston Advisors LLC boosted its position in Gilead Sciences by 13.8% in the first quarter. Boston Advisors LLC now owns 738,651 shares of the biopharmaceutical company’s stock worth $67,852,000 after buying an additional 89,302 shares during the period. Narwhal Capital Management boosted its position in Gilead Sciences by 22.3% in the first quarter. Narwhal Capital Management now owns 23,965 shares of the biopharmaceutical company’s stock worth $2,201,000 after buying an additional 4,375 shares during the period. Finally, Kelman Lazarov Inc. acquired a new position in Gilead Sciences during the first quarter worth approximately $651,000. 77.94% of the stock is owned by institutional investors.
A number of equities analysts have recently weighed in on the company. Jefferies Group upped their target price on Gilead Sciences from $91.00 to $93.00 and gave the company a “buy” rating in a report on Wednesday. RBC Capital Markets reiterated a “buy” rating and issued a $95.00 target price (down previously from $105.00) on shares of Gilead Sciences in a report on Monday. Royal Bank Of Canada upped their target price on Gilead Sciences from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Monday. Leerink Swann reiterated an “outperform” rating and issued a $112.00 target price on shares of Gilead Sciences in a report on Friday, September 30th. Finally, Goldman Sachs Group Inc. reiterated a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Tuesday, September 27th. Ten investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $104.71.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.